ArcticZymes Technologies ASA (OSE: AZT) and Brenntag Specialties Pharma today announced the signing of an exclusive distribution agreement for ArcticZymes’ SAN-HQ and M-SAN enzyme products across Europe. Under this agreement, Brenntag will act as the exclusive distributor for these products, while ArcticZymes will continue to maintain direct relationships with customers in the region.
This collaboration marks the most recent implementation of ArcticZymes new channel strategy and will significantly enhance the accessibility of ArcticZymes’ innovative salt-active nuclease in Europe. These products are used in a broad range of bioprocessing applications including the rapidly growing areas of gene therapy, vaccine manufacturing, and other advanced therapeutic modalities.
The SAN-HQ and M-SAN enzymes from ArcticZymes offer technically superior performance under both physiological and high-salt conditions, providing reliable and efficient removal of nucleic acids in complex manufacturing environments. ArcticZymes is the only company to offer specific nuclease solutions, designed and optimised to work at physiological or high salt concentrations.
- M-SAN is optimised for use with processes which favour physiological salt concentrations.
- SAN-HQ is designed for application which required a salt concentration, to reduce aggregates.
Both enzymes are available in research and GMP-grade formats, ensuring a smooth transition from development to full-scale commercial manufacturing.
Paul Blackburn, Chief Commercial Officer of ArcticZymes Technologies, commented:
“This partnership with Brenntag represents an important step in expanding our presence across Europe and making our innovative salt-active nucleases more accessible to biopharmaceutical customers. Brenntag’s strong regional footprint, technical expertise, and proven customer relationships make them an ideal partner for our existing commercial team to accelerate growth and support our mission to enable advanced biomanufacturing.”
Joakim Rehné, Regional President, Brenntag Pharma EMEA, added:
“Our partnership with ArcticZymes for SAN HQ and M-SAN HQ marks a milestone in Brenntag’s commitment to the biopharmaceutical industry. By expanding our portfolio with high-quality enzymes, we support our customers from the early research phase through to full commercialization.”
Through this collaboration, both companies reaffirm their commitment to supporting the rapidly growing therapeutic bioprocessing market by delivering high-quality, compliant, and scalable enzyme solutions that meet the evolving needs of therapeutic manufacturing.
